AGA Technical Review on Perianal Crohn’s Disease

This literature review and the recommendations therein were prepared for the American Gastroenterological Association Clinical Practice Committee. The paper was approved by the Committee on May 18, 2003, and by the AGA Governing Board on July 25, 2003.

This report is a technical review of the normal anatomy, definitions, etiology, classification, epidemiology, diagnosis, disease activity assessment, and medical and surgical treatment of perianal Crohn’s disease. Although descriptions of surgical therapy are provided along with the indications, outcomes, and complications of surgical intervention, the reader is cautioned that this review is not meant to provide the details of how to perform the specific individual surgical procedures.

Strategy for Literature Identification

A search of the online bibliographic databases MEDLINE (1966 to August 2002) and Current Contents/Science Edition (1996 to August 2002) was performed to identify potentially relevant English-language articles. The Medical Subject Heading terms “Crohn’s disease” or “inflammatory bowel disease” or “regional enteritis” AND “fistulas” or “perianal” were used to perform keyword searches of the database. Manual searches of the reference lists from the potentially relevant papers and the proceedings from annual meetings of the American Gastroenterological Association, American College of Gastroenterology, and American Society of Colon and Rectal Surgeons from 1990 to 2003 were performed to identify additional studies that may have been missed using the computer-assisted search strategy. Studies selected were retrospective or prospective studies reporting on the classification, epidemiology, diagnosis with magnetic resonance imaging (MRI) or anorectal endoscopic ultrasonography (EUS), treatment with medical therapy, and surgical treatment of perianal Crohn’s disease. This technical review is not based solely on level 1 studies (population-based natural history studies and randomized, double-blind, placebo-controlled trials of diagnostic modalities and therapeutic interventions), because only 5 level 1 studies were identified and they do not provide a sufficient basis for an “evidence-based” technical review and medical position statement. Therefore, this technical review represents the consensus opinion of the authors based on a comprehensive review of the best available evidence.

Normal Anatomy, Definitions, Etiology, and Classification

Normal Anatomy

To understand the etiology and classification of perianal fistulas and other perianal lesions, a review of perianal anatomy is required. The anal canal consists of an inner layer of circular smooth muscle extending downward from the rectum called the internal anal sphincter, the intersphincteric space, and an outer layer of skeletal muscle extending downward from the puborectalis and levator ani muscles called the external anal sphincter (Figure 1). The dentate line, located in the midportion of the anal canal, separates the transitional and columnar epithelium of the rectum from the squamous epithelium of the anus. Anal crypts are located at the dentate line, and anal glands are found at the base of these crypts.

Definitions

The definitions for the various types of perianal lesions that occur in patients with Crohn’s disease are shown in Table 1. A perianal fistula (Latin for pipe) is a chronic track of granulation tissue connecting 2 epithelial lined surfaces. A sinus track is a track of granulation tissue that is open only at one end.

Etiology and Classification of Fistula-in-Ano

In patients without Crohn’s disease, perianal fistulas (often called fistula-in-ano or cryptogenic fistulas) usually arise from infected anal glands. In 1934, Milligan and Morgan classified fistula-in-ano according to their relationship to the anorectal ring (formed by the puborectalis muscle) as subcutaneous, low anal (below the dentate line), high anal (above the dentate line but below the anal ring formed by the puborectalis muscle), ischiorectal (above the dentate line but below the anal ring formed by the puborectalis muscle), anorectal below the levator ani muscle (ischiorectal or...
infralevator), anorectal above the levator ani muscle (pelvirectal or supralevator), and submucous (high intermuscular between the internal and external anal sphincters). The Parks classification describes 5 types of perianal fistulas: intersphincteric, transsphincteric, suprasphincteric, extraspincteric, and superficial. The presence of any branching or horseshoeing (crossing the midline anteriorly or posteriorly) and its location (intersphincteric, infralevator, and supralevator) must also be noted.

**Etiology and Classification of Perianal Crohn’s Disease**

In patients with Crohn’s disease, a variety of perianal manifestations may occur, including perianal skin lesions (anal skin tags, hemorrhoids), anal canal lesions (anal fissures, anal ulcers, anorectal strictures), perianal fistulas and abscesses, rectovaginal fistulas, and cancer. The etiology of Crohn’s perianal fistulas may be a fistula-in-ano arising from inflamed or infected anal glands and/or penetration of fissures or ulcers in the rectum or anal canal. In 1978, Hughes proposed an anatomic and pathologic classification for perianal Crohn’s disease (the Cardiff classification) in which each major manifestation of perianal Crohn’s disease (ulceration, fistula, and stricture) is graded on a scale of 0 to 2 (0, absent; 2, severe); fistulas are also classified as low (not extending above the dentate line) or high (extending above the dentate line, sometimes to the levator muscles), and other associated anal conditions, the intestinal location of other sites of Crohn’s disease, and a global assessment of the activity of the perianal disease are noted. Despite its descriptive accuracy and comprehensiveness, the Cardiff classification system has never gained widespread acceptance because of the perception by clinicians that it is of limited clinical relevance. Neither the Cardiff classification nor a more recent perianal Crohn’s Disease Activity Index score have been reproduced or prospectively validated using clinically meaningful end points.

These perianal disease classifications or indices of activity have yet to be standardized or used in clinical practice. The Parks classification system can be used to classify and describe perianal fistulas, but it does not address the other perianal manifestations of Crohn’s disease. We propose an empiric approach that we believe is relatively widely used. This empiric approach includes physical examination of the perianal area to identify anal skin tags, anal fissures, perianal fistulas, suspected perianal abscesses, anorectal strictures, and rectovaginal fis-
tulas as well as an endoscopic evaluation to determine whether or not there is macroscopically evident inflammation of the rectum. Fistulas are then classified as either "simple" or "complex." A simple fistula is low (superfi-
EUS, and pelvic MRI may be required to accurately classify some patients (see following text).

**Epidemiology**

In a combined medical and surgical Crohn’s disease follow-up clinic, 110 of 202 consecutive patients (54%) had evidence of past or current perianal complications. The types and distribution of perianal lesions are shown in Table 4.

The cumulative frequency of perianal fistulas in patients with Crohn’s disease has been reported to range from 14% to 38% in patients evaluated at referral centers, from 17% to 28% in patients undergoing surgery for Crohn’s disease, 36% in patients participating in a clinical trial, and 13% in children and adolescents at a referral center. Two population-based studies by Hellers et al. and Schwartz et al. have reported that perianal fistulas occurred in 23% and 21% of patients with Crohn’s disease, respectively. The cumulative frequency of perianal fistulas in one population-based study was 12% at 1 year, 15% at 5 years, 21% at 10 years, and 26% at 20 years (Figure 3). Perianal fistulas occurred in 12% of patients with ileal Crohn’s disease, 15% of patients with ileocolonic disease, 41% of patients with colonic disease with rectal sparing, and 92% of patients with colonic disease and rectal involvement. Anal fissure or perianal fistula or abscess precedes or presents simultaneously with the diagnosis of intestinal disease in 36%–81% of patients with Crohn’s disease who develop perianal disease. A small proportion of patients with Crohn’s disease may persist in having only isolated perianal involvement.

**Diagnosis**

Modalities used to diagnose and classify Crohn’s perianal fistulas include EUA, fistulography, computed tomography, pelvic MRI, and anorectal EUS.

**EUA**

EUA consists of visual inspection, palpation, and the passage of malleable probes into fistula tracks under general anesthesia. EUA performed by an experienced colorectal surgeon has been considered the standard against which other diagnostic modalities are judged. However, recent studies comparing EUA with consensus diagnosis, pelvic MRI, or anorectal EUS have suggested that EUA is approximately 90% accurate in detecting and correctly classifying perianal fistulas, sinuses, and abscesses. The accuracy of EUA may be enhanced by the use of intraoperative anorectal EUS with or without hydrogen peroxide contrast to enhance the sonographic identification of fistula tracks (see following text). In addition to diagnostic utility, EUA has the advantage of allowing concomitant surgical therapy such as incision and drainage of perianal abscess and placement of non-cutting setons, along with other advantages (see following text).

---

**Table 2. Hughes/Cardiff 1979 Classification of Anal Crohn’s Disease (U.F.S.)**

<table>
<thead>
<tr>
<th>Ulceration (U)</th>
<th>Fistula/abscess (F)</th>
<th>Stricture (S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not present-0</td>
<td>Lower/superficial-1</td>
<td>Reversible stricture (spasm/membranous)</td>
</tr>
<tr>
<td>b. Anovaginal</td>
<td>c. Intersphincteric</td>
<td>a. Low rectum-membranous</td>
</tr>
<tr>
<td>c. With gross skin tags</td>
<td>d. Anovaginal</td>
<td>c. Spasm with severe pain, no sepsis identified</td>
</tr>
<tr>
<td>Cavitating ulcers-2</td>
<td>High/complex-2</td>
<td>Irreversible stricture (severe fibrotic)-2</td>
</tr>
<tr>
<td>b. Lower rectum</td>
<td>b. High direct (anorectal)</td>
<td>b. Extracectral stricture</td>
</tr>
<tr>
<td>c. With extension to perineal skin</td>
<td>c. High complex</td>
<td></td>
</tr>
<tr>
<td>(aggressive ulceration)</td>
<td>d. Rectovaginal</td>
<td></td>
</tr>
<tr>
<td>e. Ileoperineal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Modified and reprinted with permission from Hughes LE.

**Table 3. 1992 Addition to the Hughes/Cardiff Classification (A.P.D.)**

<table>
<thead>
<tr>
<th>Associated anal conditions (A)</th>
<th>Proximal intestinal disease (P)</th>
<th>Disease activity (in anal locations) (D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None-0</td>
<td>No proximal disease-0</td>
<td>Active-1</td>
</tr>
<tr>
<td>Hemorrhoids-1</td>
<td>Contiguous rectal disease-1</td>
<td>Inactive-2</td>
</tr>
<tr>
<td>Malignancy-2</td>
<td>Colon (rectum spared)-2</td>
<td>Inconclusive-3</td>
</tr>
<tr>
<td>Other (specify)-3</td>
<td>Small intestine-3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Investigation incomplete-4</td>
<td></td>
</tr>
</tbody>
</table>

Modified and reprinted with permission from Hughes LE.
symptoms originate primarily from luminal disease.61 Accordingly, patients whose symptoms originate primarily from perianal fistulas usually have low Crohn’s Disease Activity Index scores.62 Thus, the Crohn’s Disease Activity Index is not suitable for measuring fistula activity.63 Present et al. were the first to attempt measurement of fistula activity using a therapeutic goals score.64 Patients were evaluated at baseline and assigned a baseline fistula activity score of 0. Fistula activity was then graded periodically using a 7-point scale that ranged from +3 to −3 based on fistula activity, with a positive number indicating improvement. This instrument is subjective and thus has not been widely used. In 1991, a working group suggested a functional classification for perianal Crohn’s disease that included assessments of effect on essential activities such as sitting, defecating, and walking; effect on quality of life such as ability to work, enjoy life, sexual relationship, and sickness index profile; symptoms of incontinence; and need for medications such as narcotics and antibiotics.8 This functional classification was never subsequently validated or used in clinical studies or clinical practice. The Perianal Disease Activity Index evaluates 5 categories affected by fistulas: discharge, pain, restriction of sexual activity, type of perianal disease, and degree of induration (Table 5).65 Each category is graded on a 5-point Likert scale ranging from 0 to 4. A higher score indicates more severe disease. The Perianal Disease Activity Index, which may in the future become the perianal disease equivalent of the Crohn’s Disease Activity Index, has yet to be fully validated; in addition, the change in Perianal Disease Activity Index score that is clinically meaningful, as well as the absolute Perianal Disease Activity Index score equating with clinical remission of perianal fistulas, have not been determined. More recently, the Fistula Drainage Assessment

### Table 4. Types of Perianal Lesions in 202 Consecutive Patients in a Crohn’s Disease Follow-up Clinic

<table>
<thead>
<tr>
<th>Type of lesion</th>
<th>Number of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin tag</td>
<td>75 (37)</td>
</tr>
<tr>
<td>Fissure</td>
<td>38 (19)</td>
</tr>
<tr>
<td>Low fistula</td>
<td>40 (20)</td>
</tr>
<tr>
<td>High fistula</td>
<td>12 (6)</td>
</tr>
<tr>
<td>Rectovaginal fistula</td>
<td>6 (3)</td>
</tr>
<tr>
<td>Perianal abscess</td>
<td>32 (16)</td>
</tr>
<tr>
<td>Ischiorectal abscess</td>
<td>8 (4)</td>
</tr>
<tr>
<td>Intersphincteric abscess</td>
<td>7 (3)</td>
</tr>
<tr>
<td>Supravaginal abscess</td>
<td>6 (3)</td>
</tr>
<tr>
<td>Anorectal stricture</td>
<td>19 (9)</td>
</tr>
<tr>
<td>Hemorrhoids</td>
<td>15 (7)</td>
</tr>
<tr>
<td>Anal ulcer</td>
<td>12 (12)</td>
</tr>
<tr>
<td>Total patients with perianal lesions</td>
<td>110 (54)</td>
</tr>
</tbody>
</table>

From Keighley and Allan.12

### Fistulography and Computed Tomography

The diagnostic accuracy of older imaging modalities such as fistulography and computed tomography for the classification of fistula-in-ano and perianal Crohn’s disease does not exceed 50%–60%, values that are generally considered too low to be clinically useful.34–45

### MRI

The techniques and findings of pelvic MRI examination of perianal Crohn’s disease have been reviewed elsewhere.46–47 Unlike fistulography and computed tomography, the diagnostic accuracy of pelvic MRI with phased-array or endoanal coils for classifying fistula-in-ano and perianal Crohn’s fistulas ranges from 76% to 100%.27–33,48,49 A number of studies have reported that pelvic MRI findings change surgical management in 10%–15% of cases.27–33 The role of serial pelvic MRI examinations to follow the response of Crohn’s perianal fistulas to medical therapies such as infliximab is unclear.50–52

### Anorectal EUS

The diagnostic accuracy of endoanal ultrasonography ranges from 56% to 100%.32,39,53–58 Also, similar to pelvic MRI, a number of studies have reported that anorectal EUS findings change surgical management in approximately 10%–15% of cases.32,57 The role of serial anorectal EUS examinations to follow the response of Crohn’s perianal fistulas to medical therapies such as infliximab is unclear.51,59,60

### Measurement of Fistula Disease Activity

The Crohn’s Disease Activity Index score was developed to measure disease activity in patients whose
has been used to classify fistulas as either open and actively draining or closed (Table 6). A fistula is open and actively draining if the investigator can express purulent material from the fistula with the application of gentle pressure. The acute effects of therapy are assessed by determining if a patient has a fistula response (defined as closure of at least 50% of fistulas present at baseline maintained for at least 4 weeks) or has complete fistula closure (defined as closure of all fistulas present at baseline maintained for at least 4 weeks). The maintenance effects of therapy are assessed by determining the time to loss of fistula response or the time to loss of complete fistula closure. The terminology “closure of fistulas” probably does not accurately reflect the findings of EUA, pelvic MRI, or anorectal EUS, which often show persistent fistula tracts even when fistula drainage has ceased; thus, alternative terminology such as “cessation of drainage” should be considered. Although not addressed by the Fistula Drainage Assessment, it should be noted that it is important to reduce or eliminate anal pain in addition to fistula drainage.

### Table 5. Perianal Crohn’s Disease Activity Index

<table>
<thead>
<tr>
<th>Categories affected by fistulas</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge</td>
<td></td>
</tr>
<tr>
<td>No discharge</td>
<td>0</td>
</tr>
<tr>
<td>Minimal mucous discharge</td>
<td>1</td>
</tr>
<tr>
<td>Moderate mucous or purulent discharge</td>
<td>2</td>
</tr>
<tr>
<td>Substantial discharge</td>
<td>3</td>
</tr>
<tr>
<td>Gross fecal soiling</td>
<td>4</td>
</tr>
<tr>
<td>Pain/restriction of activities</td>
<td></td>
</tr>
<tr>
<td>No activity restriction</td>
<td>0</td>
</tr>
<tr>
<td>Mild discomfort, no restriction</td>
<td>1</td>
</tr>
<tr>
<td>Moderate discomfort, some limitation activities</td>
<td>2</td>
</tr>
<tr>
<td>Marked discomfort, marked limitation</td>
<td>3</td>
</tr>
<tr>
<td>Severe pain, severe limitation</td>
<td>4</td>
</tr>
<tr>
<td>Restriction of sexual activity</td>
<td></td>
</tr>
<tr>
<td>No restriction in sexual activity</td>
<td>0</td>
</tr>
<tr>
<td>Slight restriction in sexual activity</td>
<td>1</td>
</tr>
<tr>
<td>Moderate limitation in sexual activity</td>
<td>2</td>
</tr>
<tr>
<td>Marked limitation in sexual activity</td>
<td>3</td>
</tr>
<tr>
<td>Unable to engage in sexual activity</td>
<td>4</td>
</tr>
<tr>
<td>Type of perianal disease</td>
<td></td>
</tr>
<tr>
<td>No perianal disease/skin tags</td>
<td>0</td>
</tr>
<tr>
<td>Anal fissure or mucosal tear</td>
<td>1</td>
</tr>
<tr>
<td>&lt;3 Perianal fistula</td>
<td>2</td>
</tr>
<tr>
<td>≥3 Perianal fistula</td>
<td>3</td>
</tr>
<tr>
<td>Anal sphincter ulceration or fistulae with significant undermining of skin</td>
<td>4</td>
</tr>
<tr>
<td>Degree of induration</td>
<td></td>
</tr>
<tr>
<td>No induration</td>
<td>0</td>
</tr>
<tr>
<td>Minimal induration</td>
<td>1</td>
</tr>
<tr>
<td>Moderate induration</td>
<td>2</td>
</tr>
<tr>
<td>Substantial induration</td>
<td>3</td>
</tr>
<tr>
<td>Gross fluctuence/abscess</td>
<td>4</td>
</tr>
</tbody>
</table>

From Irvine.65

Medical Treatment

The pharmaceutical agents with definite or potential efficacy for treating patients with perianal Crohn’s disease include antibiotics, azathioprine and 6-mercaptopurine, infliximab, cyclosporine, and tacrolimus.

Antibiotics

There are no controlled trials showing that antibiotics are effective in the treatment of Crohn’s perianal fistulas. The current clinical practice of using metronidazole or ciprofloxacin is based on uncontrolled case series and the absence of other therapeutic alternatives perceived to be safe for use in all patients. A representative experience with metronidazole is that of Bernstein et al., who reported a series of 21 patients with perianal Crohn’s disease treated with metronidazole 20 mg · kg⁻¹ · day⁻¹. All patients had a clinical response with a decrease in pain and tenderness. Ten of the 18 patients (56%) had complete healing of their perianal disease. Clinical improvement typically occurred after 6–8 weeks of therapy. A follow-up study of 17 of these patients, along with 9 additional patients, showed exacerbation of disease with dosage reduction as well as the occurrence of paresthesias in 13 of 26 patients (50%) (the paresthesias disappeared with dose reduction or drug discontinuation in 7 patients, paresthesias persisted under ongoing treatment in 5 patients, and hot/cold sensitivity persisted after drug discontinuation in 1 patient). Clinicians prescribing antibiotics for fistulas typically use metronidazole at doses ranging from 750 to 1500 mg/day or ciprofloxacin 1000 mg/day for up to 3–4 months. Adverse events associated with metronidazole include metallic taste, glossitis, nausea, and a distal peripheral sensory neuropathy. Adverse events associated with ciprofloxacin are uncommon but include headache, nausea, diarrhea, and rash. A recent cost-utility study suggested that metronidazole combined with 6-mercaptopurine was a more cost-effective treatment.

### Table 6. Fistula Drainage Assessment

<table>
<thead>
<tr>
<th>End point</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improvement</td>
<td>Closure of individual fistulas defined as no fistula drainage despite gentle finger compression. Improvement defined as a decrease from baseline in the number of open draining fistulas of ≥50% for at least 2 consecutive visits (i.e., at least 4 weeks).</td>
</tr>
<tr>
<td>Remission</td>
<td>Closure of individual fistulas defined as no fistula drainage despite gentle finger compression. Remission defined as closure of all fistulas that were draining at baseline for at least 2 consecutive visits (i.e., at least 4 weeks).</td>
</tr>
</tbody>
</table>

Modified and reprinted with permission from Present et al.62
strategy than infliximab-based treatment strategies (see following text). However, this study may have underestimated the cost of patients with fistulas; in addition, given that no controlled data support the efficacy of these agents, this conclusion is highly questionable.

**Azathioprine and 6-Mercaptopurine**

There are no controlled trials with fistula closure as the primary end point showing that the antimetabolites azathioprine and 6-mercaptopurine are effective in the treatment of Crohn’s perianal fistulas. The current clinical practice of using these medications is based on a meta-analysis of 5 controlled trials in which fistula closure was examined as a secondary end point and controlled case series in adults and children. The meta-analysis included 70 patients from 5 controlled trials of azathioprine or 6-mercaptopurine for Crohn’s disease in which the details of fistula closure were described and could be used as a secondary end point (fistula closure was identified as a secondary end point post-hoc in 4 of the 5 studies specifically for the purposes of performing the meta-analysis). The results of the meta-analysis showed that 22 of 41 patients (54%) treated with azathioprine or 6-mercaptopurine had fistula healing versus 6 of 29 patients (21%) treated with placebo, with a pooled odds ratio of 4.44 favoring healing of fistulas. Clinical practice varies widely with respect to dosing and administration of azathioprine and 6-mercaptopurine. Controlled trials indicate that azathioprine at doses of 2.0–3.0 mg·kg$^{-1}$·day$^{-1}$ and 6-mercaptopurine at a dose of 1.5 mg·kg$^{-1}$·day$^{-1}$ is effective for the treatment of Crohn’s disease. Some clinicians prefer to start either drug at a dose of 50 mg/day and gradually titrate to effect or to a “therapeutic” blood metabolite concentration to minimize the occurrence of adverse events, although the efficacy of this strategy is unproven. Adverse events associated with azathioprine and 6-mercaptopurine include leucopenia, allergic reactions, infection, pancreatitis, drug-induced hepatitis, and possibly non-Hodgkin’s lymphoma. Patients treated with these medications should have regular monitoring of leukocyte counts and liver transaminase levels.

**Infliximab**

There are 2 controlled trials in which fistula closure was the primary end point showing that infliximab (a mouse/human chimeric monoclonal antibody to tumor necrosis factor) is effective in the treatment of Crohn’s perianal fistulas. Uncontrolled case series have also suggested that infliximab is of benefit for this indication. In one placebo-controlled trial, 94 patients with draining Crohn’s fistulas (85 patients had perianal fistulas) were randomized to treatment with 3 infusions of placebo or infliximab at doses of 5 or 10 mg/kg at 0, 2, and 6 weeks. Closure of at least 50% of fistulas was maintained for at least 4 weeks (primary study end point) in 26% of placebo-treated patients when compared with 68% of patients treated with infliximab 5 mg/kg and 56% of patients treated with infliximab 10 mg/kg ($P = 0.002$ and $P = 0.02$, respectively). Closure of all fistulas was maintained for at least 4 weeks (secondary study end point) in 13% for placebo, 55% for infliximab 5 mg/kg, and 38% for infliximab 10 mg/kg ($P = 0.001$ and $P = 0.04$, respectively). The median duration of closure was 3 months. Eleven percent of the patients treated with infliximab developed a perianal abscess, possibly due to closure of the cutaneous end of the fistula tract before the rest of the fistula tract closed. In a second controlled trial, 306 patients with actively draining fistulas received 3 doses of infliximab 5 mg/kg at 0, 2, and 6 weeks.

Patients who responded to therapy (closure of at least 50% of fistulas maintained for at least 4 weeks) were then randomized into 2 groups at week 14; group I received maintenance doses of placebo every 8 weeks beginning at week 14, and group II received maintenance doses of infliximab 5 mg/kg every 8 weeks beginning at week 14. The primary end point was “the time to loss of response” through week 54. A total of 195 of 306 patients (69%) had a fistula response at week 14. The median time to loss of response through week 54 was 14 weeks for placebo-treated patients and >40 weeks for patients treated with infliximab 5 mg/kg ($P < 0.001$). At week 54, 39% of patients who received infliximab maintenance therapy had complete closure of all draining fistulas when compared with 19% of those who received placebo ($P = 0.009$). Nevertheless, a recently reported observational study suggested that many patients treated with infliximab for fistulas will still require surgical intervention. Another open study suggested that the combination of EUA and infliximab therapy for perianal fistulas led to more frequent and durable rates of healing. Adverse events observed in patients treated with infliximab include infusion reactions, delayed hypersensitivity reactions, formation of human antichimeric antibodies, formation of antinuclear antibodies and anti-double-stranded DNA antibodies, and drug-induced lupus. Concomitant immunosuppressive therapy with azathioprine, 6-mercaptopurine, or methotrexate is recommended to reduce the frequency of these reactions, which are largely due to an immunogenic response to the murine component of the chimeric antibody. There is also an increased overall rate of infections and, rarely, serious infections including pneumonia, sepsis, tuberculosis,
losis, histoplasmosis, coccidiodomycosis, listeriosis, Pneumocystis carinii pneumonia, and aspergillosis occur.\textsuperscript{93–97, 99–103} It is recommend that patients undergo purified protein derivative skin testing before treatment with infliximab.\textsuperscript{97}

**Cyclosporine**

There are no controlled trials showing that cyclosporine is an effective therapy for Crohn’s perianal fistulas. The current clinical practice of using intravenous cyclosporine is based on 10 uncontrolled case series that include a total of 64 patients.\textsuperscript{104–113} The overall initial response rate in these studies was 83%. Cyclosporine was administered as a continuous intravenous infusion (because of poor oral bioavailability with older formulations) at a dose of 4 mg \(\text{kg}^{-1} \cdot \text{day}^{-1}\). Clinical improvement occurred rapidly, typically within 7 days. Responding patients were converted to oral cyclosporine. Relapse rates were high when oral cyclosporine was discontinued.\textsuperscript{106, 111, 112, 114} Adverse events observed in patients treated with cyclosporine include renal insufficiency, hirsutism, hypertension, paresthesias, headache, seizure, tremor, gingival hyperplasia, hepatotoxicity, and an increased incidence of infection (including P. carinii pneumonia).\textsuperscript{114}

**Tacrolimus**

Uncontrolled case series have suggested that tacrolimus may be beneficial in the treatment of Crohn’s perianal fistulas.\textsuperscript{115–118} A single small placebo-controlled trial randomized 46 patients with actively draining Crohn’s fistulas (43 patients had perianal fistulas) to treatment with placebo or oral tacrolimus at an initial dose of 0.20 mg \(\text{kg}^{-1} \cdot \text{day}^{-1}\).\textsuperscript{119} Closure of at least 50% of fistulas maintained for at least 4 weeks (primary study end point) occurred in 8% of placebo-treated patients when compared with 43% of patients treated with tacrolimus \((P = 0.004)\). Closure of all fistulas maintained for at least 4 weeks (secondary study end point) was 8% for placebo and 10% for tacrolimus \((P = 0.86)\). Adverse events observed in patients treated with tacrolimus include headache, increased serum creatinine level, insomnia, leg cramps, paresthesias, and tremor, typically resolved with dose reduction. The major toxicity observed in patients treated with tacrolimus was an increase in serum creatinine level from baseline to a value \(\geq 1.5\) mg/dL (designated before the study as nephrotoxicity requiring tacrolimus dose reduction), which occurred in 8 of 21 patients (38%) treated with tacrolimus compared with 0 of 25 (0%) placebo-treated patients \((P = 0.008)\).

**Other Miscellaneous Medical Therapies**

There are no other controlled trials of other medical therapies for the treatment of Crohn’s perianal fistulas. Uncontrolled case reports and case series have reported that a number of other medical therapies might be of benefit, including elemental diet, bowel rest with total parenteral nutrition, mycophenolate mofetil, methotrexate, thalidomide, granulocyte colony-stimulating factor, and hyperbaric oxygen.\textsuperscript{120–143} Controlled trials are needed before these therapies can be recommended for routine use.

**Surgical Treatment**

Early reports from referral centers have suggested that the clinical course of perianal Crohn’s disease is relatively benign and that a low percentage of patients (approximately 10%–18%) require proctectomy, thus leading to the recommendation of a conservative approach with respect to surgery.\textsuperscript{144–146} However, population-based natural history studies and more recent reports have suggested that the rates of recurrent disease and proctectomy are relatively high, suggesting a greater role for judicious surgical intervention.\textsuperscript{24, 25, 147, 148} Crohn’s perianal disease lesions that are potential indications for surgical therapy include skin tags, hemorrhoids, anal fissures, anorectal strictures, perianal abscesses, perianal fistulas, rectovaginal fistulas, and cancer. Surgical therapies for Crohn’s perianal disease include lateral sphincterotomy in selected patients with anal fissures, dilation of anorectal strictures, incision and drainage of perianal abscess, fistulotomy, placement of noncutting setons, transanal endorectal advancement flap, intestinal resection, temporary diverting colostomy or ileostomy, and proctectomy or proctocolectomy.\textsuperscript{149} Obstetric surgical procedures involving the perineal area such as vaginal delivery and episiotomy must also be considered.

**Skin Tags**

As noted in Table 1, 2 types of skin tags may occur: (1) typical Crohn’s disease skin tags, which are large, edematous, hard, cyanotic, and often tender or painful, and (2) a variety of other skin tags including long (up to 2 cm) narrow polypoid lesions (fibroepithelial polyp) and large flat “elephant ear” tags, which are soft and painless. Although some investigators have advocated excisional biopsy of typical Crohn’s disease skin tags to aid in the diagnosis,\textsuperscript{150} the typical appearance and risk of postoperative complications, poor wound healing, and rare requisite for proctectomy preclude routine biopsy or excision.\textsuperscript{12} On the other hand, the fibroepithelial
polyoid tags and elephant ear tags can be locally excised if clinically indicated in patients experiencing difficulty with perianal hygiene/toilet without concerns about wound healing (however, excision of these innocuous tags is rarely required).

**Hemorrhoids**

Simple hemorrhoidectomy, the newer procedure for prolapsing hemorrhoids, and banding of hemorrhoids in patients with Crohn’s disease are usually contraindicated due to the frequent occurrence of postoperative complications, including poor wound healing, anorectal stenosis, and a high rate of proctectomy, notwithstanding one recent report suggesting that simple hemorrhoidectomy can be safely performed in selected patients. When symptomatic prolapsing or bleeding hemorrhoids fail to respond to conservative measures, in the absence of active anorectal Crohn’s disease, elastic band ligation may be used with great effect (Victor Fazio, unpublished experience, May 2003). It should also be noted that in patients without a preceding history/diagnosis of Crohn’s disease who have a nonhealed hemorrhoidectomy wound 2–3 months postoperatively, investigation including colonoscopy is warranted to rule out occult Crohn’s disease.

**Anal Fissures**

Anal fissures in patients with Crohn’s disease are usually painless and spontaneously heal in more than 80% of patients. Operative intervention in unselected patients does not improve the outcome and should generally be avoided. However, in patients who have pain due to the fissure itself (not to local sepsis) and who do not have macroscopic evidence of rectal inflammation, lateral sphincterotomy may achieve healing without subsequent incontinence in most patients. Fissurectomy is contraindicated. The role of topical glyceryl trinitrate, isosorbide dinitrate, diltiazem, botulinum toxin, and other pharmacologic agents that relax the anal sphincter to treat anal fissures in patients with Crohn’s disease is unknown.

**Anorectal Strictures**

Anal or rectal strictures may arise as complications of ulceration of the anal canal or rectum, perianal abscesses, and perianal fistulas and are often associated with ongoing rectal inflammation, complex perianal fistulas, and rectovaginal fistulas. Anal strictures may be short (<2 cm in length) and annular, resulting in a diaphragm-like deformity, or long and tubular. Symptoms are typically those of urgency, incontinence, tenesmus, frequency, and difficulty with defecation. Many patients are asymptomatic and do not require treatment. For symptomatic patients, treatment consists of dilation with one-finger, Hegar’s dilators not to exceed one finger’s width, or coaxial balloons. Repeat dilations are often required. Home dilators can be tried. Care must be taken to avoid overdilation with injury to the anal sphincter and incontinence. Some patients will require proctectomy. There are no clinical trials or prospective outcome data to evaluate the efficacy or durability of dilation of anorectal strictures.

**Perianal Abscess**

The presence of perianal pain, tenderness, or fluctuation in a patient with Crohn’s disease suggests the possibility that a perianal abscess may have formed as a result of a cryptoglandular infection or obstruction of a perianal fistula tract. Perianal abscesses must be drained surgically. A superficial perianal abscess can be defined as a subcutaneous perianal abscess near the skin surface, a perianal abscess close to the anal verge, an intersphincteric abscess with no cephalad extent above the dentate line, or an ischiorectal abscess inferior to the postanal space (superficial to the anococcygeal ligament). Superficial perianal abscesses may be associated with a low perianal fistula and can be treated with incision and drainage. Fistulotomy of an associated low perianal fistula should not be performed in this setting because of the risk of poor wound healing (see following text). A deep perianal abscess can be defined as a perianal abscess at some distance from the skin surface, a deep postanal space abscess (i.e., ischiorectal abscess bounded superiorly by the levator ani, inferiorly by the anococcygeal ligament and medial aspect of the external sphincter), or a supralelevator abscess (which may arise from an intersphincteric abscess or from extension of a transsphincteric abscess, or from an extraspincteric origin such as a perforated rectum or ileal Crohn’s disease perforation extending into the supralevator space). Deep perianal abscesses may be associated with a high perianal fistula and should be treated with incision and drainage, followed by placement of a non-cutting seton if an associated high perianal fistula can be identified or placement of a mushroom catheter if an associated fistula cannot be identified. The placement of setons, while allowing prolonged drainage of the abscess, in essence perpetuates a perianal fistula.
fistula. Patients who have low fistulas (superficial, low intersphincteric, low transspincteric) may be treated by laying open the fistula tract through 1- or 2-stage fistulotomy (Figure 4 and Table 7).12,18,19,21,152,155,160,165,167,168,170,171,173–180 The initial healing rates in 21 studies of fistulotomy in patients with low fistulas ranged from 8% to 100%, with healing rates of 80%–100% in 13 of 21 studies, 60%–79% in 5 of 13 studies, and ≤59% in 3 of 21 studies (Table 7). The recurrence rates in 10 studies of patients with fistulotomy who initially healed ranged from 5% to 89%, with recurrence rates of 0%–20% in 7 of 10 studies, 21%–40% in 1 of 10 studies, and ≥41% in 2 of 10 studies (Table 7). The rates of incontinence following fistulotomy range from 0% to 50%, and the rates of proctectomy or long-term diverting stoma following fistulotomy range from 6% to 60% (Table 7). The wide range of rates of recurrence, incontinence, and proctectomy may reflect differences in patient selection and referral center bias, along with other differences. In general, there is a trend toward greater healing rates following fistulotomy for low fistulas in patients without macroscopic evidence of inflammation of the rectum when compared with patients with active inflammation of the rectosigmoid colon; however, even in patients without macroscopic evidence of rectal inflammation, a nonhealing wound following fistulotomy for a low fistula will lead to proctectomy in some patients (Table 7). For this reason, many surgical experts advocate the use of a noncutting seton (see following text) rather than fistulotomy in patients with low fistulas and active inflammation of the rectosigmoid colon.

High fistulas involving a significant portion of the external anal sphincter (such as high intersphincteric, high transspincteric, suprasphincteric, or extraspincteric fistulas) require a more conservative surgical approach to reduce the risk of incontinence. Noncutting setons are the treatment of choice in patients with high fistulas who have active inflammation of the rectosigmoid colon and may also be used in patients with high fistulas who do not have macroscopic evidence of rectal inflammation.

Figure 4. In the absence of active proctocolitis, simple low transspincteric, intersphincteric, and superficial fistulas can be treated with a fistulotomy. Reprinted with permission from Schwartz et al.149
inflammation (Figure 5 and Table 8). A noncutting seton is a suture or drain that is threaded into the cutaneous orifice of a perianal fistula, through the fistula tract, and across the mucosal orifice of the fistula into the rectum and then out the anal canal (Figure 5). A noncutting seton maintains drainage of the fistula, thereby reducing the risk of perianal abscess formation. Fistulas reoccur frequently following the removal of noncutting setons (Table 8). Fistulotomy or fistula excision (fistulectomy) in patients with high fistulas has been associated with a high rate of subsequent proctectomy due to nonhealing or incontinence (Table 8). A cutting seton is formed by tying a noncutting seton tightly, causing pressure necrosis that essentially results in a slow fistulotomy that can also result in both nonhealing and incontinence. An endorectal advancement flap can be used as an alternative to fistulotomy in patients with low fistulas who do not have macroscopic evidence of rectal inflammation and similarly as an alternative to noncutting setons in patients with high fistulas who do not have macroscopic evidence of rectal inflammation (Table 8). An advancement flap consists of incising a flap of tissue (mucosa, submucosa, circular muscle) around the internal opening of a fistula, excising the internal opening of the fistula tract, and pulling the flap down to cover the opening (Figure 6). A refinement of
the technique has been used when the anal canal is ulcerated or recently affected with an active disease and where the rectum appears endoscopically normal. The advancement rectal sleeve procedure involves circumferential excision, lifting the anal canal mucosa from the dentate line to the anorectal ring, mobilization of a full-thickness rectal flap (as done in the Altemeir procedure for rectal prolapse), and anastomosis of the rectal sleeve to the dentate line.¹⁹¹ Success rates in this highly selected group of patients have been 65%.

Table 8. Results of Treatment of High or Complex Perianal Fistulas in Patients With Crohn’s Disease

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Treatment</th>
<th>Healed (%)</th>
<th>Recurrence (%)</th>
<th>Incontinence (%)</th>
<th>Proctectomy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>van Dongen et al.²⁰</td>
<td>2</td>
<td>Seton</td>
<td>2 (100)</td>
<td>0</td>
<td>Not stated</td>
<td>0</td>
</tr>
<tr>
<td>Williams et al.¹⁷³</td>
<td>22</td>
<td>Seton</td>
<td>19/22 (86)</td>
<td>9/19 (47)</td>
<td>14 (66)</td>
<td>3 (14)</td>
</tr>
<tr>
<td>Sangwan et al.¹⁷⁸</td>
<td>24</td>
<td>Seton</td>
<td>22/24 (92)</td>
<td>17/24 (63)</td>
<td>Not stated</td>
<td>7 (33)</td>
</tr>
<tr>
<td>Scott et al.¹⁷⁸</td>
<td>27</td>
<td>Seton</td>
<td>23/27 (85)</td>
<td>4/27 (15)</td>
<td>4 (15)</td>
<td>4 (15)</td>
</tr>
<tr>
<td>White et al.¹⁶⁴</td>
<td>10</td>
<td>Seton</td>
<td>10/10 (100)</td>
<td>2/10 (20)</td>
<td>Not stated</td>
<td>0</td>
</tr>
<tr>
<td>Koganei et al.¹⁷²</td>
<td>13</td>
<td>Seton</td>
<td>0 closed</td>
<td>10/13 (77)</td>
<td>3/10 (30)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Sugita et al.¹⁸¹</td>
<td>21</td>
<td>Seton</td>
<td>17/21 (81)</td>
<td>0</td>
<td>9/17 (53)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Williams et al.¹⁸²</td>
<td>23</td>
<td>Seton</td>
<td>20/23 (87)</td>
<td>8/23 (36)</td>
<td>Not stated</td>
<td>5 (22)</td>
</tr>
<tr>
<td>Faucheron et al.¹⁸³</td>
<td>41</td>
<td>Seton</td>
<td>36/41 (88)</td>
<td>11/41 (27)</td>
<td>8/36 (22)</td>
<td>5 (12)</td>
</tr>
<tr>
<td>Pearl et al.¹⁸⁴</td>
<td>21</td>
<td>Seton</td>
<td>21/21 (100)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Williamson et al.¹⁷⁰</td>
<td>9</td>
<td>Seton</td>
<td>7/9 (78)</td>
<td>2/9 (22)</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>McKee et al.¹⁷⁷</td>
<td>7</td>
<td>Seton</td>
<td>4/7 (57)</td>
<td>3/7 (43)</td>
<td>Not stated</td>
<td>2 (29)</td>
</tr>
<tr>
<td>Halm et al.¹⁷⁵</td>
<td>5</td>
<td>Seton or excision + fecal diversion</td>
<td>1 (20)</td>
<td>Not stated</td>
<td>Not stated</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Morrison et al.¹⁵²</td>
<td>2</td>
<td>Seton + lay open</td>
<td>2/2 (100)</td>
<td>Not stated</td>
<td>Not stated</td>
<td>0</td>
</tr>
<tr>
<td>Morrison et al.¹⁵²</td>
<td>2</td>
<td>Lay open</td>
<td>2/2 (100)</td>
<td>Not stated</td>
<td>Not stated</td>
<td>0</td>
</tr>
<tr>
<td>McKee et al.¹⁷⁷</td>
<td>5</td>
<td>Lay open</td>
<td>2/5 (40)</td>
<td>3/5 (60)</td>
<td>2 (40)</td>
<td>2 (40)</td>
</tr>
<tr>
<td>Halm et al.¹⁷⁵</td>
<td>1</td>
<td>Lay open</td>
<td>0</td>
<td>0</td>
<td>Not stated</td>
<td>0</td>
</tr>
<tr>
<td>Nordgren et al.¹²¹</td>
<td>10</td>
<td>Lay open</td>
<td>4/10 (40)</td>
<td>1/4 (25)</td>
<td>Not stated</td>
<td>6 (60)</td>
</tr>
<tr>
<td>Morrison et al.¹⁵²</td>
<td>2</td>
<td>Lay open and/or excision + fecal diversion</td>
<td>1/2 (50)</td>
<td>Not stated</td>
<td>Not stated</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Matos et al.¹⁸⁵</td>
<td>10</td>
<td>Excision and primary closure</td>
<td>10/10 (100)</td>
<td>6/10 (60)</td>
<td>5/10 (50)</td>
<td>0</td>
</tr>
<tr>
<td>Jones et al.¹⁸⁶</td>
<td>6</td>
<td>Transanal full-thickness advancement flap</td>
<td>2/6 (33)</td>
<td>4/6 (67)</td>
<td>Not stated</td>
<td>1 (17)</td>
</tr>
<tr>
<td>Fry et al.¹⁶⁷</td>
<td>3</td>
<td>Transanal advancement flap</td>
<td>3/3 (100)</td>
<td>0</td>
<td>Not stated</td>
<td>0</td>
</tr>
<tr>
<td>Lewis et al.¹⁸⁷</td>
<td>6</td>
<td>Transanal advancement flap</td>
<td>5/6 (83)</td>
<td>1/6 (17)</td>
<td>Not stated</td>
<td>0</td>
</tr>
<tr>
<td>Makowiec et al.¹⁸⁸</td>
<td>20</td>
<td>Transanal advancement flap</td>
<td>16/20 (80)</td>
<td>4/20 (20)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Joo et al.¹⁸⁹</td>
<td>26</td>
<td>Transanal advancement flap</td>
<td>19/26 (73)</td>
<td>7/26 (27)</td>
<td>Not stated</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Robertson et al.¹⁹⁰</td>
<td>6</td>
<td>Transanal advancement flap</td>
<td>3/6 (50)</td>
<td>3/6 (50)</td>
<td>Not stated</td>
<td>0</td>
</tr>
<tr>
<td>Williamson et al.¹⁷⁰</td>
<td>4</td>
<td>Transanal advancement flap</td>
<td>1/4 (25)</td>
<td>3/4 (75)</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>McKee et al.¹⁷⁷</td>
<td>2</td>
<td>Transanal advancement flap</td>
<td>1/2 (50)</td>
<td>1/2 (50)</td>
<td>Not stated</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Marchesa et al.¹⁹¹</td>
<td>13</td>
<td>Sleeve advancement flap</td>
<td>8/13 (62)</td>
<td>5/13 (38)</td>
<td>Not stated</td>
<td>3 (23)</td>
</tr>
</tbody>
</table>

the technique has been used when the anal canal is ulcerated or recently affected with an active disease and where the rectum appears endoscopically normal. The advancement rectal sleeve procedure involves circumferential excision, lifting the anal canal mucosa from the dentate line to the anorectal ring, mobilization of a full-thickness rectal flap (as done in the Altemeir procedure for rectal prolapse), and anastomosis of the rectal sleeve to the dentate line.¹⁹¹ Success rates in this highly selected group of patients have been 65%.

Placement of a temporary diverting ileostomy or colostomy has been used to treat severe perianal Crohn’s disease. The rationale for fecal diversion is to reduce fecal flow across the fistula tract by reducing flow through the rectum, allowing the rectal mucosa to heal and the fistula to close. Fecal diversion procedures are now only rarely performed as a primary therapy after a number of studies showed that patients who undergo placement of a temporary diverting ileostomy or colostomy for perianal Crohn’s disease almost never have intestinal continuity restored.¹⁹²⁻¹⁹⁷ A second rationale for diverting ileostomy is that significant perianal sepsis poses a major risk for an unhealed perianal wound when proctectomy or protocolectomy is required. Subsidence of active sepsis
by preliminary fecal diversion may lessen the risk of the unhealed perianal wound at the time of definitive resection. Historically, the proctectomy rate for perianal Crohn’s disease in conservatively managed patients ranges from 10% to 18%. Whether the more frequent use of noncutting setons and treatment with infliximab has reduced the frequency of proctectomy has not yet been determined.

Rectovaginal Fistulas

Surgical treatment of rectovaginal fistulas in patients with perianal Crohn’s disease should only be attempted in the absence of active inflammation of the rectosigmoid colon. Although there are reports of patients with low fistulas (superficial, low intersphincteric, low transsphincteric) being treated by laying open the fistula tract through conventional fistulotomy (Table 9), this procedure should rarely, if ever, be used in patients with rectovaginal fistulas; anterior fistulotomy in this setting is considered very hazardous due to sphincter injury risk. Patients with rectovaginal fistulas may be treated by a number of other approaches, including primary closure, transanal advancement flap, sleeve advancement flap, and transvaginal advancement flap (Table 9). Although there are reports of patients with rectovaginal fistulas being treated with placement of a noncutting seton (Table 9), this procedure should rarely, if ever, be used in patients with rectovaginal fistulas; placement of noncutting setons in this setting tends to enlarge the opening, making the fistula more symptomatic. An exception is when there is a rectovaginal septal abscess or inflammatory mass in addition to the fistulas. In this circumstance, drainage of the inflamed septum may be enhanced by a noncutting seton. In general, the success rates for primary closure and advancement flaps in patients with rectovaginal fistulas range from approximately 50% to 100%.

Obstetric Surgical Procedures (Vaginal Delivery and Episiotomy)

One study suggested that vaginal delivery led to an exacerbation of perianal disease in patients with a history of perianal disease independent of the activity of the perianal disease at the time of delivery, whereas another study suggested that worsening of perianal disease was limited to those women with active perianal disease at the time of vaginal delivery. Based on these data, it is recommended that pregnant female patients with active perianal Crohn’s disease at the time of delivery undergo cesarean section, whereas patients with no history of perianal disease and those with inactive perianal disease can undergo vaginal delivery in the absence of other indications for cesarean section.

Cancer

Case reports and case series have identified patients with Crohn’s perianal disease in whom squamous cell carcinoma, basal cell carcinoma, and adenocarcinoma have developed in chronic perianal fistula or sinus tracts. The possibility of malignancy should always be considered when examining nonhealing fistulas, and curettage or biopsy of the fistulous tract and histologic review of the curetted or biopsy material should be performed when cancer is suspected or when risk factors for cancer (e.g., longstanding fistulas) are present. When cancer is identified in a fistula track, standard oncologic surgical principles and procedures should be followed.
Approach to Treatment

The treatment of perianal fistulas in patients with Crohn’s disease should be approached with knowledge of the relevant perianal anatomy, diagnostic modalities, and medical and surgical treatment options. The therapeutic plan devised for each patient must take into account the activity of the proximal luminal Crohn’s disease and, in particular, disease activity in the rectum, the location and type of fistulas present, and the severity of the patient’s symptoms.

Diagnosis

To plan appropriate medical or surgical therapy, patients with perianal Crohn’s disease are classified as having simple fistulas or complex perianal disease. As previously described, simple fistulas are low, have a single external opening, and do not have associated perianal abscess, rectovaginal fistula, anorectal stricture, or macroscopically evident rectal inflammation; complex fistulas are high and/or have multiple external openings, perianal abscess, rectovaginal fistula, anorectal stricture, or macroscopic evidence of rectal inflammation. Diagnosis of simple fistulas or complex perianal disease by physical examination and rectosigmoid endoscopy may be sufficient for many patients when medical therapy is the initial treatment strategy (Figure 7), although one preliminary report suggests that EUA before medical therapy with infliximab led to more frequent and durable rates of clinical response by identifying perianal abscesses that were not suspected based on physical examination.94 Additional diagnostic evaluation by EUA and either anorectal EUS or pelvic MRI is indicated in those patients with pain, fluctuation, or stricture on digital rectal examination and in those patients in whom surgical therapy is the initial treatment strategy, because up to 10% of patients with perianal fistulas will be misclassified by EUA alone (Figure 7).27–33 In addition, fistulotomy of a high fistula misclassified as a low fistula may lead to incontinence and/or poor wound healing and in some instances subsequent proctectomy. It is recognized that this recommendation represents a change in practice, even for gastroenterologists and colorectal surgeons.

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Type of repair</th>
<th>Healed (%)</th>
<th>Proctectomy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francois et al.9</td>
<td>9</td>
<td>Lay open</td>
<td>9 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Hudson198</td>
<td>5</td>
<td>Lay open</td>
<td>3 (60)</td>
<td>0</td>
</tr>
<tr>
<td>Faulconer et al.199</td>
<td>3</td>
<td>Lay open</td>
<td>0</td>
<td>2 (67)</td>
</tr>
<tr>
<td>Givel et al.200</td>
<td>1</td>
<td>Lay open</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Bandy et al.201</td>
<td>1</td>
<td>Lay open</td>
<td>1 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Radcliffe et al.202</td>
<td>12</td>
<td>Lay open</td>
<td>6 (50)</td>
<td>4 (33)</td>
</tr>
<tr>
<td>Williams et al.173</td>
<td>1</td>
<td>Lay open</td>
<td>0</td>
<td>1 (100)</td>
</tr>
<tr>
<td>O’Leary et al.203</td>
<td>1</td>
<td>Lay open</td>
<td>1 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Hudson198</td>
<td>4</td>
<td>Primary closure</td>
<td>3 (75)</td>
<td>0</td>
</tr>
<tr>
<td>Tuxen et al.204</td>
<td>2</td>
<td>Primary closure</td>
<td>1 (50)</td>
<td>0</td>
</tr>
<tr>
<td>Givel et al.200</td>
<td>2</td>
<td>Primary closure</td>
<td>1 (50)</td>
<td>0</td>
</tr>
<tr>
<td>Bandy et al.201</td>
<td>9</td>
<td>Primary closure</td>
<td>8 (89)</td>
<td>0</td>
</tr>
<tr>
<td>Cohen et al.205</td>
<td>6</td>
<td>Primary closure</td>
<td>3 (50)</td>
<td>1 + 1 ileostomy (33)</td>
</tr>
<tr>
<td>O’Leary et al.203</td>
<td>2</td>
<td>Primary closure</td>
<td>1 (50)</td>
<td>0</td>
</tr>
<tr>
<td>Wiskind et al.206</td>
<td>3</td>
<td>Primary closure</td>
<td>3 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Radcliffe et al.202</td>
<td>4</td>
<td>Primary closure</td>
<td>2 (50)</td>
<td>3/15 (20)*</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Anterior advancement flap</td>
<td>3 (60)</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Transanal advancement flap</td>
<td>4 (67)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Transanal full-thickness advancement flap</td>
<td>1 (100)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Transanal endorectal mucosal flap</td>
<td>2 (67)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Transanal advancement flap</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Transanal anocutaneous flap</td>
<td>7 (70)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Transanal advancement flap</td>
<td>10 (83)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>Curvilinear advancement flap</td>
<td>13 (54)</td>
<td>3 (13)</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Linear advancement flap</td>
<td>3 (50)</td>
<td>1 (17)</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Transanal advancement flap</td>
<td>3 (50)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>Transanal advancement flap</td>
<td>4 (25)</td>
<td>11 (69)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Sleeve advancement flap</td>
<td>3 (60)</td>
<td>1 (20)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Sleeve advancement</td>
<td>2 (100)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>Transvaginal flap</td>
<td>13 (93)</td>
<td>1 ileostomy (7)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Seton</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Details regarding rates of proctectomy for 3 types of repair not provided.
with great expertise in the management of perianal Crohn’s disease, but acknowledges that EUA is not 100% accurate and that inaccurate diagnosis before surgical intervention may lead to irreversible functional consequences. In addition, EUA and either anorectal EUS or pelvic MRI should be considered in all patients with a simple fistula or complex perianal disease who fail medical or surgical therapy to identify remediable causes of treatment failure.

**General Treatment of Crohn’s Disease**

In addition to the specific medical and surgical treatments outlined as follows, any active proximal luminal disease should also be treated as appropriate with budesonide, conventional corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, and surgical resection. Postoperative bile salt diarrhea or steatorrhea should be treated as indicated with loperamide, diphenoxylate and atropine, codeine, cholestyramine, and low-fat diet. These measures are all aimed at reducing stool liquidity, with the goal of decreasing the quantity of fistula drainage, thus optimizing the opportunity for the fistula to close.

**Specific Treatment of Simple Perianal Fistulas**

The treatment goal for patients with simple fistulas should be cure, ideally without the requirement for long-term maintenance therapy that is administered primarily to suppress recurrence of the fistula. Potential treatments for simple fistulas include antibiotics, fistulotomy, and possibly azathioprine or 6-mercaptopurine and infliximab (Figure 7). Antibiotics are widely used to treat simple fistulas and are recommended in practice guidelines and previous treatment algorithms but have not been evaluated in placebo-controlled trials. Fistulotomy is widely used by surgeons to treat simple fistulas, and this procedure results in a high rate of healing that is often sustained. The prevailing view among surgeons is that those patients with a simple fistula who do not respond to a short course of antibiotics are best treated with fistulotomy. However, reported surgical series have been small, there are no controlled trials comparing fistulotomy with sham operation or medical therapy, and some patients fail to heal and may require proctectomy. The immunosuppressive medications azathioprine and 6-mercaptopurine can be used to treat simple fistulas and are recommended in practice guidelines but have not been evaluated in placebo-controlled trials in which fistula reduction or closure was the primary end point. Many experts believe that the rate of response in patients in whom the indication for treatment is draining fistulas is lower than in those patients with other treatment indications. Furthermore, these agents are slow acting and thus may be of more utility for maintaining fistula closure than for the initial induction of fistula closure. Infliximab has been proven effective in placebo-controlled trials for the indications of both reduction in the number of draining fistulas and maintenance of that reduction, and a 3-dose induction regimen as well as an every 8-week maintenance regimen are approved by the U.S. Food and Drug Administration for treatment of fistulas; however, infliximab is expensive, concomitant immunosuppressive therapy is probably required to counteract the formation of human antichimeric antibodies that may lead to infusion reactions and loss of efficacy, and rarely serious infections may occur. There are insufficient high-quality data (level 1 evidence) to make a clear recommendation as to whether antibiotics, fistulotomy, azathioprine or 6-mercaptopurine, or infliximab is the preferred strategy for simple fistulas. It is possible that “curative” fistulotomy may have a lower economic cost than induction and maintenance therapy with infliximab, but caution should be used in accepting this conclusion because there are insufficient prospec-
tively collected data detailing the morbidity (rates of incontinence and proctectomy) following fistulotomy. Additionally, there are insufficient data to determine whether long-term maintenance therapy with infliximab is required in patients with simple fistulas who respond to induction therapy. Tacrolimus and cyclosporine are not appropriate treatment for simple fistulas because of toxicity.

**Specific Treatment of Complex Perianal Fistulas**

The treatment goal for patients with complex fistulas is typically fistula closure and then suppression of recurrence. Potential treatments for complex fistulas include antibiotics, azathioprine and 6-mercaptopurine, infliximab, and surgery (dilation of anal strictures, placement of noncutting setons, endorectal advancement flap, repair of rectovaginal fistulas, fecal diversion, and proctectomy) (Figure 7). Tacrolimus and cyclosporine may rarely be used in selected patients. Antibiotics are widely used to treat complex fistulas and are recommended in practice guidelines and treatment algorithms[19,222] but have not been evaluated in placebo-controlled trials. Relapse rates for complex fistulas are high after antibiotic therapy is discontinued, and their use should probably be adjunctive in combination with other medical agents or surgery in this setting. Similarly, the immunosuppressive medications azathioprine and 6-mercaptopurine have been used to treat complex fistulas and are recommended in practice guidelines[19,222] but have not been evaluated in placebo-controlled trials for fistula closure. These agents are slow acting and thus are of more utility for maintaining fistula closure than for the initial induction of fistula closure. In contrast to antibiotics and immunosuppressive medications, infliximab has been proven to be effective in placebo-controlled trials for reduction in the number of draining fistulas and maintenance of that reduction, and treatment of fistulas with a 3-dose induction regimen and an every 8-week maintenance regimen of infliximab is approved by the Food and Drug Administration; although therapy with infliximab is expensive and concomitant immunosuppressive therapy is probably required, these factors are of less consequence in patients with complex perianal fistulas who have an otherwise poor prognosis. Surgical therapy for complex perianal disease is largely palliative. Perianal abscesses should be drained and anal strictures dilated. Noncutting setons can be placed in fistula tracts in patients with macroscopic rectal inflammation, and endorectal advancement flap procedures for high perianal fistulas and rectovaginal fistulas can be performed in patients without rectal inflammation. However, the recurrence rates following removal of noncutting setons and following endorectal advancement flap procedures are both relatively high. Setons can be left in place indefinitely; however, given the alternative of suppressive medical therapy, patients may not prefer this option. Fistulotomy and cutting setons are relatively contraindicated due to risk of nonhealing and incontinence. Because infliximab therapy can completely close all fistula tracks in many patients with complex fistulas, most gastroenterologists now believe that infliximab is the initial treatment of choice in this setting (it is debated by surgeons whether infliximab or noncutting setons is the initial treatment of choice for the subgroup of patients with complex perianal fistulas who do not have active rectal disease, because there are no data on patient acceptance of long-term noncutting setons versus treatment with infliximab). In patients treated with infliximab, azathioprine, 6-mercaptopurine, or methotrexate should be initiated before or coadministered routinely both to counteract an immunogenic reaction to infliximab and as maintenance of remission therapy. Many patients will require combination maintenance therapy with azathioprine, 6-mercaptopurine, or methotrexate and infliximab. Temporary adjunctive therapy with antibiotics may be considered. It is clear from clinical trials with infliximab that routine EUA and seton placement before initiating infliximab therapy is not mandatory. Whether or not the outcome with infliximab therapy for complex fistulas is improved through a multimodality approach that includes both temporary placement of setons and therapy with infliximab, azathioprine or 6-mercaptopurine, and an antibiotic is unknown. The rationale for such an approach is that the temporary placement of setons guarantees resolution of sepsis (which can be a reason for infliximab failure); the setons are removed after 1 or 2 doses of infliximab to allow the fistulas to close. Patients with complex fistulas who initially fail treatment with infliximab should undergo anorectal EUS or pelvic MRI as well as EUA with placement of setons as indicated while continuing treatment with infliximab, azathioprine or 6-mercaptopurine, and antibiotics. Tacrolimus or cyclosporine can rarely be considered in selected patients who fail multimodality treatment with other medical and surgical therapies, including infliximab.[222] This practice is based on uncontrolled case series with cyclosporine and a single short-term placebo-controlled trial with tacrolimus that showed a reduction in the number of draining fistulas; however, nephrotoxicity and other side effects occur frequently and should be used with caution. In addition, the trials examining tacrolimus and cyclosporine have
been of short duration, without determining whether maintenance therapy after initial fistula closure is safe and effective. As a last resort, fecal diversion or proctectomy may be undertaken.

**Specific Treatment of Rectovaginal Fistulas**

The treatment goals for patients with rectovaginal fistulas are initially to decrease fistula drainage to a minimal level that is “acceptable” or ideally to completely close the fistula, then suppression of recurrence, and then cure if possible. Potential treatments for rectovaginal fistulas include both medical therapy and surgery. 6-Mercaptopurine, infliximab, cyclosporine, and tacrolimus have all been used to treat rectovaginal fistulas in uncontrolled series.81,90,106,112,117 A recent controlled trial of maintenance infliximab infusions in patients with fistulas who responded to infliximab included a subgroup of patients with rectovaginal fistulas.89 In general, the rates of closure for rectovaginal fistulas appear to be lower than for perianal fistulas. Surgical treatment of rectovaginal fistulas can only be performed when there is endoscopic healing of the rectosigmoid mucosa. Thus, standard medical therapy with conventional corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, and infliximab should be administered as indicated to control active luminal inflammatory disease in the rectosigmoid colon.222 Other perianal disease should be treated as previously outlined. If the rectovaginal fistula persists after the patient has received medical therapy to treat both the fistula itself and the rectosigmoid mucosa and there is no evidence of an anorectal stricture or active rectal disease, then surgical repair with transanal or transvaginal advancement flaps, or laparotomy with primary closure or sleeve advancement flap, can be performed. Temporary diverting ileostomy or colostomy may be performed simultaneously in selected cases. If the advancement flap procedures (which involve coring out the fistula) fail, the rectovaginal fistula may actually increase in size and result in a worsening of symptoms. Thus, advancement flap surgery should be reserved for patients with disabling symptoms (by their definition), that is, stool per vagina, recurrent vaginitis, and vulvar excoriation. As a last resort, fecal diversion or proctectomy may be undertaken. Some women in whom rectovaginal fistula drainage has diminished but not stopped following medical and/or surgical therapy may choose to accept residual fistula drainage over proctectomy with an ostomy to optimize their overall quality of life.

**Conclusions**

Perianal disease occurs frequently in patients with Crohn’s disease. Diagnostic evaluation with physical examination and rectosigmoid endoscopy, supplemented in some cases with EUA and anorectal ultrasonography or pelvic MRI, is required to determine the location and type of fistulas and the presence or absence of macroscopic rectal inflammation. Skin tags and hemorrhoids should not be operated on. Most anal fissures should not be operated on. Lateral sphincterotomy can be considered in selected cases. Anorectal strictures should be dilated and perianal abscesses drained. Simple fistulas can be treated with antibiotics, infliximab, or fistulotomy. The treatment goal is cure without suppressive maintenance therapy. Complex perianal disease should be treated initially with infliximab and azathioprine or 6-mercaptopurine, followed by maintenance therapy with azathioprine or 6-mercaptopurine, in some cases combined with infliximab. Antibiotics may be used as adjunctive therapy during the induction phase of treatment. EUA and placement of noncutting setons or performing endorectal advancement flap procedures is reserved for patients who fail a trial of medical therapy. Tacrolimus or cyclosporine can rarely be considered in selected patients who fail multimodality treatment with other medical and surgical therapies, including infliximab, before proceeding to fecal diversion or proctectomy.

**WILLIAM J. SANDBORN**

Mayo Clinic
Rochester, Minnesota

**VICTOR W. FAZIO**

Cleveland Clinic
Cleveland, Ohio

**BRIAN G. FEAGAN**

University of Western Ontario
London, Ontario, Canada

**STEPHEN B. HANAUER**

University of Chicago
Chicago, Illinois

**References**

29. deSouza NM, Hall AS, Puni R, Gilderdale DJ, Young IR, Kmiot WA. High resolution magnetic resonance imaging of the anal sphincter using a dedicated endoanal coil. Comparison of magnetic resonance imaging with surgical findings. Dis Colon Rectum 1996;39:926–934.
49. Koebel G, Schmiedl U, Majer MC, Weber P, Jennis H, Kueper K,


75. Wolf JL. Ciprofloxacin may be useful in Crohn’s disease (abstr). Gastroenterology 1990;98:A212.


179. Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-


216. Ying LT, Hurlbut DJ, Depew WT, Boag AH, Taguchi K. Primary


Address requests for reprints to: Chair, Clinical Practice Committee, AGA National Office, c/o Membership Department, 4930 Del Ray Avenue, Bethesda, Maryland 20814. Fax: (301) 654-5920.

W. J. S. has consulted for Prometheus Laboratories, GlaxoSmithKline, Centocor, Novartis, and Fujisawa. He has received research support from Prometheus Laboratories, Schering-Plough, Centocor, and Fujisawa. He has participated in continuing medical education events indirectly sponsored by Prometheus Laboratories, Schering-Plough, and Centocor. B. G. F. has consulted for Centocor and Novartis. He has received research support from Schering-Plough and Centocor. He has participated in continuing medical education events indirectly sponsored by Schering-Plough and Centocor.

The Clinical Practice Committee thanks the following individuals whose critiques of this review paper provided valuable guidance to the authors: Jeffrey L. Barnett, M.D., Geert D’Haens, M.D., Ph.D., Francis A. Farraye, M.D., M.Sc., Jeffrey A. Katz, M.D., and Gary R. Lichtenstein, M.D.